Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 55 | 8,457 | 47% |
| 2020 | 52 | 7,926 | 49% |
| 2021 | 43 | 7,260 | 51% |
| 2022 | 44 | 6,063 | 53% |
| 2023 | 35 | 5,590 | 56% |
| 2024 | 34 | 4,796 | 58% |
| 2025 from claims | – | 4,788 4,394–5,066 | 59% |
| 2026 forecast | – | 4,855 4,272–5,603 | 59% |
| 2027 forecast | – | 4,861 4,156–5,793 | 59% |
| 2028 forecast | – | 4,866 4,060–5,959 | 60% |
| 2029 forecast | – | 4,871 3,978–6,108 | 60% |
| 2030 forecast | – | 4,874 3,905–6,246 | 61% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 60% of the cases CMS names in Pennsylvania; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 44% inpatient hospital, 40% hospital outpatient, 7% surgery center, 9% office. The share outside the hospital has moved −10 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.5 | 60% | 16,300 in 2030+4.6%/yr |
| New Jersey | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.0 | 77% | 12,700 in 2030+6.4%/yr |
| Massachusetts | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.5 | 43% | 4,060 in 2030+3.1%/yr |
| Connecticut | 14 | 1,650−9%/yr | −9%/yr | 4.7 | 71% | 1,560 in 2030−1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.3 | 0% | 1,240 in 2030+15%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.5 | 0% | 260 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 59 | 4,916−14%/yr | −14%/yr | 3.80.6× | 50% | 4,300 in 2030−2.2%/yr |
| Superficial venous ablation | 45 | 3,315−8.9%/yr | −8.9%/yr | 2.30.6× | 87% | 3,220 in 2030−0.5%/yr |
| Thrombectomy, IVC filters & venous stents | 14 | 1,998+1.6%/yr | +1.6%/yr | 1.51.1× | 9% | 2,310 in 2030+2.4%/yr |
| Carotid revascularization | 23 | 1,666−3.1%/yr | −3.1%/yr | 1.21.3× | 0% | 1,760 in 2030+0.9%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 705−5.5%/yr | −5.5%/yr | 0.51.3× | 0% | 710 in 2030+0.1%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
W L Gore & Associates leads with 34% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 11 companies reported engagement with Pennsylvania’s surgeons worth $120K in consulting, speaking, meals and travel tied to these products, about $3,528 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.